Amylin-Based Therapeutics Summit 2026

Memo

The amylin analog space is rapidly expanding in 2026, with new companies entering the field, stealth programs beginning to emerge, and major investment from Roche-Zealand Pharma and AbbVie-Gubra reinforcing growing confidence in the modality. With biology still being unlocked and multiple development paths on the table, there remains headroom to define best-in-class amylin therapeutics, open new indications, and shape how this therapeutic area will deliver differentiated, durable benefit. For companies that get the science right, the competitive upside is significant. The inaugural Amylin-Based Therapeutics Summit 2026 arrives at this critical inflection point. This is the first and only industry-dedicated forum bringing biopharma and academia together to dive deep and explore the full breadth of amylin drug development - from foundational receptor biology to late-stage clinical strategy. Across two immersive days, learn from and connect with pioneering minds from Novo Nordisk, Eli Lilly, Zealand Pharma, iBio, I2O Therapeutics and emerging innovators who are collectively shaping the field. URLs:Tickets: https://go.evvnt.com/3798499-2?pid=5569Brochure: https://go.evvnt.com/3798499-3?pid=5569 Date and Time: On Tue, 01 Dec 2026 08:00 - Thu, 03 Dec 2026 15:00 Venue Details: Wyndham Boston Beacon Hill, 5 Blossom Street, Boston, Massachusetts, 02114, United States Category: Conferences | Science, Health and Medicine | Pharmaceuticals Prices:Drug Developer Pricing - 3 Day Pass (Conference + Workshop Day): USD 4397.00,Drug Developer Pricing - 3 Day Pass (Conference + One Workshop): USD 3748.00,Drug Developer Pricing - 2 Day Pass (Conference Only): USD 3099.00,Academic and Research Pricing - 3 Day Pass (Conference + Workshop Day): USD 3797.00,Academic and Research Pricing - 3 Day Pass (Conference + One Workshop): USD 3248.00,Academic and Research Pricing - 2 Day Pass (Conference Only): USD 2699.00,Solution Provider Pricing - 3 Day Pass (Conference + Workshop Day): USD 5297.00,Solution Provider Pricing - 3 Day Pass (Conference + One Workshop): USD 4548.00,Solution Provider Pricing - 2 Day Pass (Conference Only): USD 3799.00 Speakers: Anna Secher, Director, Scientific, Novo Nordisk, Ved Srivastava, Chief Scientific Officer, Perpetual Medicines, Thomas Lutz, Professor, University of Zurich, Jay Olson, Research Analyst, Oppenheimer and Company, Daniel Briere, Senior Director, Eli Lilly, Mads Tang-Christensen, Chief Scientific Officer, Antag Therapeutics, Alice Fitzpatrick, Director, Gene Therapy, Fractyl Laboratories, Bin Zhu, Vice President, Business Development, GeneScience Pharmaceuticals, Cody Moore, Director, Platform Development, iBio, Kirsten Raun, Vice President, Scientific, Novo Nordisk, Cristina Rondinone, Founder and Chief Executive Officer, Pep2Tango, Augen Pioszak, Associate Professor, Department of Biochemistry and Physiology, University of Oklahoma, Martin Brenner, Chief Executive Officer and Chief Scientific Officer, iBio, Gabriel Smolarz, Vice President, US Medical Affairs and Medical Advisor, Zealand Pharma, Brent Meadows, Chief Business Officer, Senovia Biosciences, Debbie Hay, Professor, Pharmacology, Otago University, Andrew Young, Chief Scientific and Medical Officer, I2O Therapeutics